are biosimilars similar enough?
Published 7 years ago • 60 plays • Length 3:30Download video MP4
Download video MP3
Similar videos
-
2:40
understanding biosimilars
-
1:32
the regulation of biosimilars
-
4:05
the biosimilar regulatory pathway
-
3:09
biosimilars vs. generic drugs
-
1:23
misconceptions about the use of biosimilars
-
2:43
why do we need biosimilars?
-
1:42
advantages of using biosimilars
-
3:13
approaching the treatment of r/r myeloma in brazil: available options and current challenges
-
13:14
(review) review of biosimilar
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
4:38
ovg research: legacy
-
1:18
can biosimilars ensure access to drugs for everyone?
-
3:16
how will biosimilars save us money?
-
5:28
the potential impact of biosimilars in hematology
-
2:39
biosimilars: breaking down barriers of prejudice
-
1:38
the genomic definition of high-risk myeloma
-
9:34
important topics from the mpn congress 2024: addressing the risk of transformation to acute leukemia
-
0:58
dr. hurvitz on the clinical use of biosimilars in oncology
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
0:54
the importance of genomics-based stratification in multiple myeloma
-
2:27
ascembl: asciminib versus bosutinib in third-line treatment of cp-cml
-
1:30
a phase i trial of voruciclib /- venetoclax for the treatment of nhl and aml